Evolent Health Inc. (NYSE:EVH) General Counsel Jonathan Weinberg sold 10,339 shares of Evolent Health stock in a transaction that occurred on Wednesday, September 14th. The shares were sold at an average price of $21.54, for a total transaction of $222,702.06. Following the completion of the transaction, the general counsel now directly owns 76,245 shares in the company, valued at $1,642,317.30. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Evolent Health Inc. (NYSE:EVH) opened at 22.71 on Tuesday. The firm’s market cap is $1.37 billion. Evolent Health Inc. has a one year low of $8.14 and a one year high of $26.84. The stock’s 50 day moving average is $24.35 and its 200-day moving average is $17.14.

Evolent Health (NYSE:EVH) last announced its quarterly earnings results on Thursday, August 4th. The company reported ($0.12) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.16) by $0.04. The company had revenue of $56.50 million for the quarter, compared to analysts’ expectations of $51.96 million. Evolent Health had a negative net margin of 76.55% and a negative return on equity of 5.04%. Evolent Health’s revenue was up 443.3% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.95) EPS. On average, equities research analysts expect that Evolent Health Inc. will post ($0.54) earnings per share for the current fiscal year.

A number of research analysts recently issued reports on the stock. Canaccord Genuity assumed coverage on shares of Evolent Health in a research note on Wednesday, June 1st. They issued a “buy” rating on the stock. FBR & Co boosted their target price on shares of Evolent Health from $16.00 to $24.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 13th. Leerink Swann reaffirmed an “outperform” rating and set a $20.00 target price on shares of Evolent Health in a research note on Sunday, July 17th. Finally, Jefferies Group began coverage on shares of Evolent Health in a research note on Tuesday, July 26th. They set a “buy” rating and a $28.00 target price on the stock. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $22.50.

Several hedge funds have recently made changes to their positions in EVH. Pennant Capital Management LLC boosted its stake in shares of Evolent Health by 54.2% in the first quarter. Pennant Capital Management LLC now owns 1,361,147 shares of the company’s stock worth $14,374,000 after buying an additional 478,318 shares during the last quarter. JPMorgan Chase & Co. boosted its stake in shares of Evolent Health by 39.0% in the first quarter. JPMorgan Chase & Co. now owns 1,290,465 shares of the company’s stock worth $13,628,000 after buying an additional 361,945 shares during the last quarter. Perceptive Advisors LLC boosted its stake in shares of Evolent Health by 41.1% in the second quarter. Perceptive Advisors LLC now owns 873,064 shares of the company’s stock worth $16,763,000 after buying an additional 254,134 shares during the last quarter. Blair William & Co. IL boosted its stake in shares of Evolent Health by 205.5% in the second quarter. Blair William & Co. IL now owns 341,570 shares of the company’s stock worth $6,558,000 after buying an additional 229,748 shares during the last quarter. Finally, TimesSquare Capital Management LLC boosted its stake in shares of Evolent Health by 21.1% in the first quarter. TimesSquare Capital Management LLC now owns 1,192,755 shares of the company’s stock worth $12,595,000 after buying an additional 207,755 shares during the last quarter. Institutional investors own 42.07% of the company’s stock.

About Evolent Health

Evolent Health, Inc supports integrated health systems in their migration towards value-based care and population health management. The Company’s services include providing customers with a population management platform, integrated data and analytics capabilities, pharmacy benefit management services and health plan administration services.

5 Day Chart for NYSE:EVH

Receive News & Ratings for Evolent Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.